Información del artículo
Abstract
The tumor lysis syndrome (TLS) is a life-threatening complication caused by the massive release of nucleic acids, potassium and phosphate into the blood. This complication is the result of tumor cell lysis, which may occur due to treatment of drug sensitive and is characterized by rapid capacity of proliferation, that is often hematological origin. Moreover, the TLS can be observed before starting the treatment due to spontaneous tumor cell death, and frequently worsens when chemotherapy is initiated. TLS has high mortality, so that its prevention continues to be the most important therapeutic measure. In the intensive care unit (ICU), physicians should be aware of the clinical characteristics of TLS, which results in severe electrolyte metabolism disorders, especially hyperkalemia, hyperphosphatemia and hypocalcemia, and acute kidney injury which is a major cause of ICU mortality. An adequate strategy for the management of the TLS, combining hydration, urate oxidase, and an early admission to ICU can control this complication in most patients. The aim of this review is to provide diagnostic tools that allow to the ICU physician to recognize the population at high risk for developing the TLS, and outline a proper strategy for treating and preventing this serious complication.
Keywords:
Tumor lysis
Acute kidney injury
Critically ill patient
Resumen
El síndrome de lisis tumoral (SLT) es una complicación potencialmente letal provocada por la liberación masiva de ácidos nucleicos, potasio y fosfato hacia la circulación sistémica. Este cuadro es el resultado de la lisis celular de neoplasias, con frecuencia hematológicas, las cuales se caracterizan por una rápida capacidad de proliferación y alta sensibilidad a fármacos. Por otra parte, el SLT se puede observar por muerte celular espontánea previo al inicio del tratamiento citorreductor, agravándose luego de iniciada la quimioterapia. El SLT presenta una alta mortalidad, por lo que su prevención continúa siendo la medida terapéutica más importante. En la unidad de cuidados intensivos los médicos deben conocer su cuadro clínico, el cual se caracteriza por la existencia de graves trastornos del metabolismo hidroelectrolítico, en particular hiperpotasemia, hiperfosfatemia e hipocalcemia y por la aparición de una lesión renal aguda. Una adecuada intervención terapéutica implica la rápida admisión a unidad de cuidados intensivos, hidratación intravenosa y aporte de la enzima urato-oxidasa como las medidas más importantes. El objetivo de la presente revisión es proporcionar herramientas diagnósticas y terapéuticas que le permiten al médico intensivista reconocer la población en riesgo de desarrollar este síndrome, así como establecer una adecuada estrategia terapéutica y profiláctica.
Palabras clave:
Lisis tumoral
Fallo renal agudo
Paciente crítico
El Texto completo está disponible en PDF
References
[1.]
S.F. Taccone, A.A. Artigas, C.L. Sprung, R. Moreno, Y. Sakr, J.L. Vincent.
Characteristics and outcome of cancer patients in Europeans ICUs.
Crit Care, 13 (2009), pp. R15
[2.]
M. Soares, P. Caruso, E. Silva, J.M. Teles, S.M. Lobo, G. Friedman, et al.
Characteristics and outcome of patients with cancer requiring admission to intensive care units: A prospective multicenter study.
Crit Care Med, 38 (2010), pp. 9-15
[3.]
E. Azoulay, G. Thiéry, S. Chevret, D. Moreau, M. Darmon, A. Bergeron, et al.
The prognosis of acute respiratory failure in critically ill cancer patients.
Medicine, 83 (2004), pp. 360-370
[4.]
J. Bedrna, J. Polcák.
Akuter harnleiterverschluss nach bestrahlung chronischer leukämien mit röntgenstrahlen.
Med Klin, 25 (1929), pp. 1700-1701
[5.]
K.R. Hande, G.C. Garrow.
Acute tumor lysis syndrome inn patients with high grade non-Hodgkin's lymphoma.
Am J Med, 94 (1993), pp. 133-139
[6.]
M.S. Cairo, M. Bishop.
Tumor lysis syndrome: New therapeutic strategies and classification.
Br J Haematol, 127 (2004), pp. 3-11
[7.]
J. Hochberg, M. Cairo.
Tumor lysis syndrome: current perspective.
Haematologica, 93 (2008), pp. 9-13
[8.]
G.P. Kalemkerian, B. Darwish, M.L. Varterasian.
Tumor lysis syndrome in small cell carcinoma and other solid tumors.
Am J Med, 103 (1997), pp. 363-367
[9.]
A.B. Fassas, K.R. Desikan, D. Siegel, T.A. Golper, N.C. Munshi, B. Barlogie, et al.
Tumour lysis syndrome complicating high-dose treatment in patients with multiple myeloma.
Br J Haematol, 105 (1999), pp. 938-941
[10.]
J.E. Gold, S.C. Malamud, F. LaRosa, M.E. Osband.
Adoptive chemoimmunotherapy using ex vivo activated memory T-cells and cyclophosphamide: tumor lysis syndrome of a metastatic soft tissue sarcoma.
Am J Hematol, 44 (1993), pp. 42-47
[11.]
S.F. Bilgrami, B.G. Fallon.
Tumor lysis syndrome after combination chemotherapy for ovarian cancer.
Med Pediatr Oncol, 21 (1993), pp. 521-524
[12.]
A.I. Shamseddine, A.M. Khalil, M.H. Wehbeh.
Acute tumor lysis syndrome with squamous cell carcinoma of the vulva.
Gynecol Oncol, 51 (1993), pp. 258-260
[13.]
E. Vaisban, A. Braester, O. Mosenzon, M. Kolin, Y. Horn.
Spontaneous tumor lysis syndrome in solid tumors: really a rare condition?.
Am J Med Sci, 325 (2003), pp. 38-40
[14.]
D.R. Crittenden, G.L. Ackerman.
Hyperuricemic acute renal failure in disseminated carcinoma.
Arch Intern Med, 137 (1977), pp. 97-99
[15.]
J. Stoves, D. Richardson, H. Patel.
Tumour lysis syndrome in a patient with metastasic melanoma treated with biochemorapy.
Nephrol Dial Transplant, 323 (2001), pp. 188-189
[16.]
C. Gemici.
Tumour lysis syndrome in solid tumours.
Clin Oncol, 1 (2006), pp. 773-780
[17.]
P. Montesinos, I. Lorenzo, G. Martín, J. Sanz, M.L. Pérez-Sirvent, G. Ortí, et al.
Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and developmentof a predictive model.
Haematologica, 93 (2008), pp. 67-74
[18.]
N. Sklarin, M. Markham.
Spontaneous tumor lysis syndrome.
Am J Clin Oncol, 18 (1995), pp. 71-73
[19.]
B.D. Cheson, J.N. Frame, D. Vena, N. Quashu, J.M. Sorensen.
Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia.
J Clin Oncol, 16 (1998), pp. 2313-2320
[20.]
L. Annemans, K. Moeremans, M. Lamotte, J. García Conde, H. Van der Berg, H. Myint, et al.
Incidence, medical utilisation and costs of hyperuricemia and tumor lysis syndrome in patients with acute leukemia and non-Hodgkin's lymphoma in four European countries.
Leuk Lymphoma, 44 (2003), pp. 77-83
[21.]
V. Pumo, D. Sciacca, M. Malaguarnera.
Tumor lysis syndrome in ederly.
Crit Rev Oncol Hematol, 64 (2007), pp. 31-42
[22.]
P. Tosi, G. Barosi, C. Lazzaro, V. Liso, M. Marchetti, E. Morra, et al.
Consensus conference on the management of tumor lysis syndrome.
Haematologica, 93 (2008), pp. 1785-1877
[23.]
A.S. Michallet, S. Tartas, B. Coiffier.
Optimizing management of tumor lysis syndrome in adults with hamatologic malignancies.
Support Cancer Ther, 2 (2005), pp. 159-166
[24.]
C.D. Flombaum.
Metabolic emergencies in hte cancer patient.
Semin Oncol, 27 (2000), pp. 322-334
[25.]
E.D. Simmons, K.A. Sonberg.
Acute tumor lysis syndrome after intrathecal methotrexate administration.
Cancer, 67 (1991), pp. 2062-2065
[26.]
A. Gafter-Gvili, R. Ram, U. Gater, O. Shpilberg, P. Raanani.
Renal failure associated with tyrosine kinase inhibitors- Case report and review of the the literature.
Leuk Res, 34 (2010), pp. 123-127
[27.]
N. Fuente, J.M. Mane, R. Barcelo, A. Muñoz, T. Perez-Hoyos, G. Lopez-Vivanco.
Tumor lysis syndrome in a multiple myeloma treated with thalidomide.
Ann Oncol, 15 (2004), pp. 537
[28.]
E. Terpos, M. Politou, A. Rahemtulla.
Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration.
J Cancer Res Clin Oncol, 1 (2004), pp. 623-625
[29.]
L. Canny, O. Fitoussi, J.M. Boiron, G. Marit.
Tumor lysis syndrome at the beginning of thalidomide therapy for multiple myelome.
J Clin Oncol, 20 (2002), pp. 2212
[30.]
S.M. Moe.
Disorders involving calcium, pfospforus, and magnesium.
Prim Care, 35 (2008), pp. 215-237
[31.]
M. Shimada, R.J. Johnson, W.S. May, V. Lingegowda, P. Sood, T. Nakagawa, et al.
A novel role for uric acid in acute kidney injury associated with tumor lysis syndrome.
Nephrol Dial Transplant, 24 (2009), pp. 2960-2964
[32.]
C.A. Roncal, W. Mu, B. Croker, S. Reungjui, X. Ouyang, Tabah-FischI., et al.
Effect of elevated serum uric acid on cisplatin-induced acute renal failure.
Am J Physiol Renal Physiol, 292 (2007), pp. F116-F122
[33.]
Antineoplastic Agents.
Drug Facts and Comparisons.0 Web, St Louis.
Wolters Kluwer Health, Inc, (2009),
[34.]
R.T. Skeel.
Handbook of cancer chemotherapy.
7th ed., Lippincott, (2007),
[35.]
S. Spinazzé, D. Schrijvers.
Metabolic emergencies.
Crit Rev Oncol Hematol, 58 (2006), pp. 79-89
[36.]
N. Zojer, H. Ludwig.
Hematological emergencies.
Ann Oncol, 18 (2007), pp. i145-i148
[37.]
B. Coiffer, A. Altman, C. Pui, A. Younes, M.S. Cairo.
Guidelines for management of pediatric and adult tumor lysis syndrome: an evidence-based review.
J Clin Oncol, 26 (2008), pp. 2767-2778
[38.]
A.A. Yarpuzlu.
A review of clinical and laboratory findings and treatment of tumor lysis syndrome.
Clin Chim Acta, 333 (2003), pp. 13-18
[39.]
A. Karagiannis, I. Tsoralis, A. Kakafika, P. Pateinakis, V. Perifanis, F. Harsoulis.
Acute renal failure due to tumor lysis syndrome in a patient with non-Hodgkin's lymphoma.
Ann Hematol, 8 (2005), pp. 343-346
[40.]
R.V. Tiu, S.E. Mountantonakis, A.J. Dunbar, M.J. schreiber.
Tumor lysis syndrome.
Semin Thromb Hemost, 33 (2007), pp. 397-407
[41.]
J.D. Conger, S.A. Falk.
Intrarenal dynamics in the pthogenesis and prevention of acute urate nephopathy.
J Clin Invest, 59 (1977), pp. 786-793
[42.]
R.V. Smalley, A. Guaspari, S. Haase-Statz, S.A. Anderson, D. Cederberg, J.A. Hohneker.
Allopurinol: intravenous use for prevention and treatment of hyperuricemia.
J Clin Oncol, 18 (2000), pp. 1758-1763
[43.]
P.R. Band, D.S. Silverberg, J.F. Henderson, R.A. Ulan, R.H. Wensel, T.K. Banerjee, et al.
Xantine nephropathy in a patient with lymphosarcoma treated with allopurinol.
N Engl J Med, 283 (1970), pp. 354-357
[44.]
L. Cammalleri, M. Malaguarnera.
Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and gout.
Int J Med Sci, 4 (2007), pp. 83-93
[45.]
S. Jeha, H. Kantarjian, D. Irwin, V. Shen, S. Shenoy, S. Blaney, et al.
Efficacy and safety of rasburicase, a recombinant urate oxidase (ElitekTM), in the management of malignancyassociated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial.
Leukemia, 19 (2005), pp. 34-38
[46.]
W.Y. Teo, T.F. Loh, A.M. Tan.
Avoiding dialysis in tumor lysis syndrome: is urate oxidase effective? A case report end review of literature.
Ann Acad Med Sigapore, 36 (2007), pp. 679-683
[47.]
M. Campara, S.S. Shord, D. Bcop, M. Haaf.
Single-dose rasburicase for tumor lysis syndrome in adults: weight.based approach.
J Clin Pharm Therap, 34 (2009), pp. 207-213
[48.]
A. Kikuchi, H. Kigasawa, M. Tsurusawa, K. Kawa, A. Kikuta, M. Tsuchida, et al.
A study of rasburicase for the managment of hyperuricemia in pediatric patients with diagnosed hematologic malignancies at high risk for tumor lysis syndrome.
Int J Hematol, 90 (2009), pp. 492-500
[49.]
S.C. Goldman, J.S. Hokenberg, J.Z. Finklestein, R. Hutchinson, S. Kreissman, F.L. Johnson, et al.
A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.
Blood, 97 (2001), pp. 2998-3003
[50.]
I. Rényi, E. Bárdi, E. Udvardi, G. Kovács, K. Bartyik, P. Kajtár, et al.
Prevention and treatment of hyperuricemia with rasburicase in choldren with leukemia and non-Hodgkin's lymphoma.
Pathol Oncol Res, 13 (2007), pp. 57-62
[51.]
V. Sánchez Tatay, J.D. López Castilla, J.M. Carmona Ponce, J.M. Pérez Hurtado, E. Quiroga Cantero, M. Loscertales Abril.
Rasburicasa versus alopurinol como tratamiento de la hiperuricemia en el síndrome de lisis tumoral.
An Pediatr (Barc), 72 (2010), pp. 103-110
[52.]
M. Darmon, M. Ciroldi, G. Thiery, B. Schlemmer, E. Azoulay.
Clinical review: specific aspects of acute renal failure in cancer patients.
Crit Care, 10 (2006), pp. 211-217
[53.]
K.A. Choi, J.E. Lee, Y.G. Kim, D.J. Kim, K. Kim, Y.H. Ko, et al.
Efficacy of continous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome.
Ann Hematol, 88 (2009), pp. 639-645
[54.]
M. Soares, J.I. Salluh, M.S. Carvalho, M. Darmon, J.R. Rocco, N. Spector.
Prognosis of critically ill patients with cancer and acute renal dysfunction.
J Clin Oncol, 24 (2006), pp. 4003-4010
[55.]
J. Hochberg, M.S. Cairo.
Tumor lysis syndrome: current perspective.
Haematologica, 93 (2008), pp. 9-13
[56.]
T.R. Halfdanarson, W.J. Hogan, T.J. Moynihan.
Oncologic emergencies: diagnosis and treatment.
Mayo Clin Proc, 81 (2006), pp. 835-848
[57.]
J.H. Feusner, A.K. Richey, S.L. Cohn, A.L. Billet.
Management of tumor lysis syndrome: need for evidence-based guidelines.
J Clin Oncol, (2008), pp. 5657
[58.]
F. Llinares, A. Burgos, P. Fernández, B. Villarubia, P. Ferrandis, J.P. Ordovás.
Análisis y protocolización de la utilización de rasburicasa en pacientes con neoplasias hematológicas.
Farm Hosp, 30 (2006), pp. 92-98
[59.]
M.A. Gertz.
Managing tumor lysis syndrome in 2010.
Leuk Limphoma, 51 (2010), pp. 179-180
[60.]
M. Darmon, I. Guichard, F. Vincent, B. Schlemmer, E. Azoulay.
Prognostic of acute renal injury in acute tumor lysis syndrome.
Leuk Lymphoma, 51 (2010), pp. 221-227
[61.]
T.L. Mughal, A. Ejaz, J.R. Foringer, B. Coiffier.
An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome.
Cancer Treatments Rev, 36 (2010), pp. 164-176
Copyright © 2011. Elsevier y Sociedad Española de Medicina Intensiva, Critica y Unidades Coronarias
